BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mosci C, Pericole FV, Oliveira GB, Delamain MT, Takahashi MES, Carvalheira JBC, Etchebehere ECSC, Santos AO, Miranda ECM, Lima MCL, Amorim BJ, de Souza CA, Lorand-Metze I, Ramos CD. 99mTc-sestamibi SPECT/CT and 18F-FDG-PET/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma. Nucl Med Commun 2020;41:1081-8. [PMID: 32732603 DOI: 10.1097/MNM.0000000000001259] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Tataru OS, Marchioni M, Crocetto F, Barone B, Lucarelli G, Del Giudice F, Busetto GM, Veccia A, Lo Giudice A, Russo GI, Luzzago S, Piccinelli ML, Vartolomei MD, Musi G, Ferro M. Molecular Imaging Diagnosis of Renal Cancer Using (99m)Tc-Sestamibi SPECT/CT and Girentuximab PET-CT-Current Evidence and Future Development of Novel Techniques. Diagnostics (Basel) 2023;13. [PMID: 36832081 DOI: 10.3390/diagnostics13040593] [Reference Citation Analysis]
2 Alqahtani FF. SPECT/CT and PET/CT, related radiopharmaceuticals, and areas of application and comparison. Saudi Pharm J 2023;31:312-28. [PMID: 36942267 DOI: 10.1016/j.jsps.2022.12.013] [Reference Citation Analysis]
3 Zhang YH, He YF, Yue H, Zhang YN, Shi L, Jin B, Dong P. Solitary hyoid plasmacytoma with unicentric Castleman disease: A case report and review of literature. World J Clin Cases 2022; 10(36): 13364-13372 [DOI: 10.12998/wjcc.v10.i36.13364] [Reference Citation Analysis]
4 Zhang S, Shang J, Ye W, Zhao T, Xu H, Zeng H, Wang L. Recent developments on the application of molecular probes in multiple myeloma: Beyond [18F]FDG. Front Bioeng Biotechnol 2022;10:920882. [DOI: 10.3389/fbioe.2022.920882] [Reference Citation Analysis]
5 Tagliafico AS, Valle C, Bonaffini PA, Attieh A, Bauckneht M, Belgioia L, Bignotti B, Brunetti N, Bonsignore A, Capaccio E, De Giorgis S, Garlaschi A, Morbelli S, Rossi F, Torri L, Caprioli S, Tosto S, Cea M, Dominietto A. Myeloma Spine and Bone Damage Score (MSBDS) on Whole-Body Computed Tomography (WBCT): Multiple Reader Agreement in a Multicenter Reliability Study. Diagnostics 2022;12:1894. [DOI: 10.3390/diagnostics12081894] [Reference Citation Analysis]
6 Gebreslassie KS, Bassa FC, Chapanduka ZC, Warwick JM. The relationship between bone marrow involvement on 18F-FDG PET/CT and bone marrow biopsy in patients with multiple myeloma and other plasma cell neoplasms. S Afr j oncol 2022;6. [DOI: 10.4102/sajo.v6i0.197] [Reference Citation Analysis]
7 Almeida LS, de Souza SPM, de Souza FVP, Reis F, Ramos CD. Multimodality Molecular Imaging in Arthropathy Associated with Multiple Myeloma. Indian J Nucl Med 2022;37:290-2. [PMID: 36686291 DOI: 10.4103/ijnm.ijnm_205_21] [Reference Citation Analysis]
8 Takahashi MES, Lorand-Metze I, de Souza CA, Mesquita CT, Fernandes FA, Carvalheira JBC, Ramos CD. Metabolic Volume Measurements in Multiple Myeloma. Metabolites 2021;11. [PMID: 34940633 DOI: 10.3390/metabo11120875] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]